Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that it has launched the first licensed generic version of ledipasvir+sofosbuvir combination in Nepal, under its brand name HepcinatLP.

Ledipasvir+Sofosbuvir is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences, Inc., under its brand HARVONI®. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. NATCO priced its generic medicine, Hepcinat LP, at an MRP of INR 25,000/- for a bottle of 28 tablets in Nepal.

Natco had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of HARVONI®, in India and other 100 developing countries.